Kolkata, West Bengal -- (SBWIRE) -- 09/23/2013 -- Lakeway, NY -- (SBWIRE) -- 09/23/2013-- Specialpennystockalert.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on American International Group Inc(NYSE:AIG), Walter Energy, Inc. (NYSE:WLT), Dendreon Corporation(NASDAQ:DNDN).
American International Group Inc(NYSE:AIG) shares gained 0.18% to $49.95. Equities research analysts at Guggenheim began coverage on shares of AIG in a research note issued to investors on Sept. 18. The firm set a “neutral” rating on the stock.
Additionally, the company will begin trading ex-dividend on September 10, 2013. A cash dividend payment of $0.1 per share is scheduled to be paid on September 26, 2013. Shareholders who purchased AIG stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an -54.55% decrease from the prior year.
Should Investors Buy AIG After Yesterday’s Jump? Find Out Here
Walter Energy, Inc. (NYSE:WLT) shares decreased 8.32% to $13.77. The company on Sept. 19 announced that it has increased the size of its previously announced offering of $350 million aggregate principal amount of senior secured notes due 2019 to $450 million with a coupon of 9.500% per annum (the "Notes"). Walter Energy will pay interest on the Notes on April 15 and October 15 of each year, beginning on April 15, 2014. The Notes will be guaranteed by each of Walter Energy's current and future wholly-owned domestic restricted subsidiaries that from time to time guarantees any of Walter Energy's indebtedness or any indebtedness of any of Walter Energy's restricted subsidiaries. The Notes and related guarantees will be secured on a first priority basis by substantially all of the property and assets of Walter Energy and the guarantors.
How Should Investors Trade WLT After The Recent Volatility? Get Free Trend Analysis Here
Dendreon Corporation(NASDAQ:DNDN) shares declined 4.98% to $3.05. The company on Sept. 17 announced that the European Commission (EC) has granted marketing authorization for PROVENGE® (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) dispersion for infusion in the European Union (EU) for the treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated. This final decision by the EC follows recent positive opinions from both the European Medicines Agency (EMA) Committee for Advanced Therapy (CAT) and the Committee for Medicinal Products for Human Use (CHMP) recommending that PROVENGE be granted marketing authorization in the EU.
Should Investors Buy DNDN After Yesterday’s Jump? Find Out Here
Specialpennystockalert.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Specialpennystockalert.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.
The assembled information disseminated by Specialpennystockalert.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Specialpennystockalert.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)